Crescel's Skin Renewal Cream shows promise in rosacea clinical trial

Crescel LLC has released results from a clinical trial testing its Skin Renewal Cream against standard rosacea treatments. The study tracked 60 adults with mild to severe symptoms over 12 weeks. Early findings suggest the cream may offer a more effective option for managing the condition.

The trial compared Crescel's biobotanical cream, which uses a proprietary microemulsion system, to a widely used standard treatment. By Week 8, participants using Crescel saw a 74% drop in inflammatory lesions, while the standard group experienced only a 17% reduction. However, the difference was not statistically significant.

By Week 12, redness decreased by 54% in the Crescel group, compared to 23% in the standard care group. No participants reported side effects, and the product was well tolerated throughout the study. Dr. Roberta Shapiro, Crescel's Senior Medical Advisor, highlighted the cream's healing potential. CEO Peter J. Passalacqua, Jr., called the results a step toward a new approach in rosacea management. The product has also earned recognition from the National Rosacea Society and the National Psoriasis Foundation.

Crescel Skin Renewal Cream is now available for purchase online at www.crescel.com. The trial focused only on rosacea, with no verified studies supporting claims for other skin conditions like eczema, psoriasis, or acne as of March 2026. The company has not announced further research into broader dermatological uses.